Alcon bought Aerie Pharmaceuticals Aerie Pharmaceuticals from 11/22/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Alcon completed its acquisition of Aerie Pharmaceuticals for $770 million, or 15.25 per share.

Aerie Pharmaceuticals

Review

Source:

{source} pictogram

investor.alcon.com

Vladimir Petenev

News editor

Write your comment first

News feed

Sovcombank will allocate 30% of 2023 profit for dividends

2/16/24 SVCB

Uralsib bailout completed ahead of schedule

2/16/24 USBN

Sovcombank intends to buy Home Bank

2/16/24 SVCB

Cherkizovo Group reported for 2023 by IFRS

2/16/24 GCHE

Reason for suspension of trades in IMCB shares was their growth

2/16/24 GEMA

OGK-2 reported for 2023 by RAS

2/16/24 OGKB

Seligdar selects technology for processing Kyuchus ores

2/16/24 SELG

Pharmsintez sold the Estonian plant to the chairman of the board of directors

2/16/24 LIFE

Maria Shevchenko resigns as Chief Operating Officer of Qiwi

2/16/24 QIWI

NKNH postponed launch of hexene production to mid-2025

2/16/24 NKNC